ECMETABOLISM

Targeting endothelial metabolism: a novel anti-angiogenic therapy

Coordinatore	VIB    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Belgium [BE]
Totale costo	2˙365˙224 €
EC contributo	2˙365˙224 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2010-AdG_20100317
Funding Scheme	ERC-AG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-05-01   -   2016-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	VIB  Organization address address: Rijvisschestraat 120 city: ZWIJNAARDE - GENT postcode: 9052 contact info Titolo: Mr. Nome: Rik Cognome: Audenaert Email: send email Telefono: +32 9 2446611 Fax: +32 9 2446610	BE (ZWIJNAARDE - GENT)	hostInstitution	2˙365˙224.00
2	VIB  Organization address address: Rijvisschestraat 120 city: ZWIJNAARDE - GENT postcode: 9052 contact info Titolo: Prof. Nome: Peter Frans Martha Cognome: Carmeliet Email: send email Telefono: +32 16 345774 Fax: +32 16 345990	BE (ZWIJNAARDE - GENT)	hostInstitution	2˙365˙224.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Current anti-angiogenesis based anti-tumor therapy relies on starving tumors by blocking their vascular supply via inhibition of growth factors. However, limitations such as resistance and toxicity, mandate conceptually distinct approaches. We will explore an entirely novel and long-overlooked strategy to discover additional anti-angiogenic candidates, based on the following innovative concept: ¿rather than STARVING TUMORS BY BLOCKING THEIR VASCULAR SUPPLY, we intend TO STARVE BLOOD VESSELS BY BLOCKING THEIR METABOLIC ENERGY SUPPLY¿, so that new vessels cannot form and nourish the growing tumor. This project is a completely new research avenue in our group, but we expect that it will offer refreshing long-term research and translational opportunities for the field.

Because so little is known on endothelial cell (EC) metabolism, we will (i) via a multi-disciplinary systems-biology approach of transcriptomics, proteomics, computational network modeling, metabolomics and flux-omics, draw an endothelio-metabolic map in angiogenesis. This will allow us to identify metabolic regulators of angiogenesis, which will be further validated and characterized in (ii) loss and gain-of-function studies in various angiogenesis models in vitro and (iii) in vivo in zebrafish (knockdown; zinc finger nuclease mediated knockout), providing prescreen data to select the most promising candidates. (iv) EC-specific down-regulation (miR RNAi) or knockout studies of selected candidates in mice will confirm their relevance for angiogenic phenotypes in a preclinical model; and ultimately (v) a translational study evaluating EC metabolism-targeted anti-angiogenic strategies (pharmacological inhibitors, antibodies, small molecular compounds) will be performed in tumor models in the mouse.'